Department of Molecular Engineering, Amgen Inc., Cambridge, MA, United States of America.
Amgen Postdoctoral Fellow Program, Cambridge, MA, United States of America.
PLoS One. 2019 May 1;14(5):e0216095. doi: 10.1371/journal.pone.0216095. eCollection 2019.
Trastuzumab and pertuzumab are monoclonal antibodies that bind to distinct subdomains of the extracellular domain of human epidermal growth factor receptor 2 (HER2). Adding these monoclonal antibodies to the treatment regimen of HER2-positive breast cancer has changed the paradigm for treatment in that form of cancer. Synergistic activity has been observed with the combination of these two antibodies leading to hypotheses regarding the mechanism(s) and to the development of bispecific antibodies to maximize the clinical effect further. Although the individual crystal structures of HER2-trastuzumab and HER2-pertuzumab revealed the distinct binding sites and provided the structural basis for their anti-tumor activities, detailed structural information on the HER2-trastuzumab-pertuzumab complex has been elusive. Here we present the cryo-EM structure of HER2-trastuzumab-pertuzumab at 4.36 Å resolution. Comparison with the binary complexes reveals no cooperative interaction between trastuzumab and pertuzumab, and provides key insights into the design of novel, high-avidity bispecific molecules with potentially greater clinical efficacy.
曲妥珠单抗和帕妥珠单抗是两种单克隆抗体,它们分别结合于人表皮生长因子受体 2(HER2)细胞外结构域的不同亚结构域。将这两种单克隆抗体添加到 HER2 阳性乳腺癌的治疗方案中,改变了这种癌症的治疗模式。这两种抗体联合使用具有协同作用,这促使人们对其作用机制进行假设,并开发双特异性抗体以进一步提高临床疗效。虽然 HER2-曲妥珠单抗和 HER2-帕妥珠单抗的单个晶体结构揭示了不同的结合位点,并为其抗肿瘤活性提供了结构基础,但关于 HER2-曲妥珠单抗-帕妥珠单抗复合物的详细结构信息仍然难以捉摸。在这里,我们展示了分辨率为 4.36 Å 的 HER2-曲妥珠单抗-帕妥珠单抗的冷冻电镜结构。与二元复合物的比较表明,曲妥珠单抗和帕妥珠单抗之间没有协同相互作用,并为设计具有潜在更高临床疗效的新型高亲和力双特异性分子提供了关键见解。